360 related articles for article (PubMed ID: 32659313)
1. Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results.
Fleischer DM; Shreffler WG; Campbell DE; Green TD; Anvari S; Assa'ad A; Bégin P; Beyer K; Bird JA; Brown-Whitehorn T; Byrne A; Chan ES; Cheema A; Chinthrajah S; Chong HJ; Davis CM; Ford LS; Gagnon R; Greenhawt M; Hourihane JO; Jones SM; Kim EH; Lange L; Lanser BJ; Leonard S; Mahler V; Maronna A; Nowak-Wegrzyn A; Oriel RC; O'Sullivan M; Petroni D; Pongracic JA; Prescott SL; Schneider LC; Smith P; Staab D; Sussman G; Wood R; Yang WH; Lambert R; Peillon A; Bois T; Sampson HA
J Allergy Clin Immunol; 2020 Oct; 146(4):863-874. PubMed ID: 32659313
[TBL] [Abstract][Full Text] [Related]
2. Improvements in Quality of Life in Children Following Epicutaneous Immunotherapy (EPIT) for Peanut Allergy in the PEPITES and PEOPLE Studies.
DunnGalvin A; Fleischer DM; Campbell DE; O'B Hourihane J; Green TD; Sampson HA; Greenhawt M
J Allergy Clin Immunol Pract; 2021 Jan; 9(1):216-224.e1. PubMed ID: 32841748
[TBL] [Abstract][Full Text] [Related]
3. An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial.
Fleischer DM; Chinthrajah S; Scurlock AM; Campbell DE; Green TD; Bee KJ; Peillon A; Ocheltree T; Sampson HA
Allergy Asthma Proc; 2020 Sep; 41(5):326-335. PubMed ID: 32539908
[No Abstract] [Full Text] [Related]
4. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial.
Fleischer DM; Greenhawt M; Sussman G; Bégin P; Nowak-Wegrzyn A; Petroni D; Beyer K; Brown-Whitehorn T; Hebert J; Hourihane JO; Campbell DE; Leonard S; Chinthrajah RS; Pongracic JA; Jones SM; Lange L; Chong H; Green TD; Wood R; Cheema A; Prescott SL; Smith P; Yang W; Chan ES; Byrne A; Assa'ad A; Bird JA; Kim EH; Schneider L; Davis CM; Lanser BJ; Lambert R; Shreffler W
JAMA; 2019 Mar; 321(10):946-955. PubMed ID: 30794314
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy.
Dupont C; Burks AW; Fleischer DM; Bee KJ; Chainani S; Sampson HA
Expert Rev Clin Immunol; 2024 Jun; 20(6):623-633. PubMed ID: 38323337
[TBL] [Abstract][Full Text] [Related]
6. Effect of Varying Doses of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Exposure Among Patients With Peanut Sensitivity: A Randomized Clinical Trial.
Sampson HA; Shreffler WG; Yang WH; Sussman GL; Brown-Whitehorn TF; Nadeau KC; Cheema AS; Leonard SA; Pongracic JA; Sauvage-Delebarre C; Assa'ad AH; de Blay F; Bird JA; Tilles SA; Boralevi F; Bourrier T; Hébert J; Green TD; Gerth van Wijk R; Knulst AC; Kanny G; Schneider LC; Kowalski ML; Dupont C
JAMA; 2017 Nov; 318(18):1798-1809. PubMed ID: 29136445
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
O'B Hourihane J; Beyer K; Abbas A; Fernández-Rivas M; Turner PJ; Blumchen K; Nilsson C; Ibáñez MD; Deschildre A; Muraro A; Sharma V; Erlewyn-Lajeunesse M; Zubeldia JM; De Blay F; Sauvage CD; Byrne A; Chapman J; Boralevi F; DunnGalvin A; O'Neill C; Norval D; Vereda A; Skeel B; Adelman DC; du Toit G
Lancet Child Adolesc Health; 2020 Oct; 4(10):728-739. PubMed ID: 32702315
[TBL] [Abstract][Full Text] [Related]
8. Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults.
Jones SM; Sicherer SH; Burks AW; Leung DY; Lindblad RW; Dawson P; Henning AK; Berin MC; Chiang D; Vickery BP; Pesek RD; Cho CB; Davidson WF; Plaut M; Sampson HA; Wood RA;
J Allergy Clin Immunol; 2017 Apr; 139(4):1242-1252.e9. PubMed ID: 28091362
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of daily patch application duration for epicutaneous immunotherapy for peanut allergy.
Fleischer DM; Spergel JM; Kim EH; Campbell DE; Green TD; Bee KJ; Lambert R; Ocheltree T; Sampson HA
Allergy Asthma Proc; 2020 Jul; 41(4):278-284. PubMed ID: 32517847
[No Abstract] [Full Text] [Related]
10. Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
[TBL] [Abstract][Full Text] [Related]
11. Epicutaneous immunotherapy for treatment of peanut allergy: Follow-up from the Consortium for Food Allergy Research.
Scurlock AM; Burks AW; Sicherer SH; Leung DYM; Kim EH; Henning AK; Dawson P; Lindblad RW; Berin MC; Cho CB; Davidson WF; Plaut M; Sampson HA; Wood RA; Jones SM;
J Allergy Clin Immunol; 2021 Mar; 147(3):992-1003.e5. PubMed ID: 33290772
[TBL] [Abstract][Full Text] [Related]
12. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization.
Kim EH; Yang L; Ye P; Guo R; Li Q; Kulis MD; Burks AW
J Allergy Clin Immunol; 2019 Nov; 144(5):1320-1326.e1. PubMed ID: 31493887
[TBL] [Abstract][Full Text] [Related]
13. Sublingual immunotherapy for peanut allergy: Long-term follow-up of a randomized multicenter trial.
Burks AW; Wood RA; Jones SM; Sicherer SH; Fleischer DM; Scurlock AM; Vickery BP; Liu AH; Henning AK; Lindblad R; Dawson P; Plaut M; Sampson HA;
J Allergy Clin Immunol; 2015 May; 135(5):1240-8.e1-3. PubMed ID: 25656999
[TBL] [Abstract][Full Text] [Related]
14. Estimated risk reduction to packaged food reactions by epicutaneous immunotherapy (EPIT) for peanut allergy.
Remington BC; Krone T; Kim EH; Bird JA; Green TD; Lack G; Fleischer DM; Koppelman SJ
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):488-493.e2. PubMed ID: 31442495
[TBL] [Abstract][Full Text] [Related]
15. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.
Chinthrajah RS; Purington N; Andorf S; Long A; O'Laughlin KL; Lyu SC; Manohar M; Boyd SD; Tibshirani R; Maecker H; Plaut M; Mukai K; Tsai M; Desai M; Galli SJ; Nadeau KC
Lancet; 2019 Oct; 394(10207):1437-1449. PubMed ID: 31522849
[TBL] [Abstract][Full Text] [Related]
16. Epicutaneous peanut patch device for the treatment of peanut allergy.
Langlois A; Graham F; Bégin P
Expert Rev Clin Immunol; 2019 May; 15(5):449-460. PubMed ID: 30864861
[TBL] [Abstract][Full Text] [Related]
17. Administration of a probiotic with peanut oral immunotherapy: A randomized trial.
Tang ML; Ponsonby AL; Orsini F; Tey D; Robinson M; Su EL; Licciardi P; Burks W; Donath S
J Allergy Clin Immunol; 2015 Mar; 135(3):737-44.e8. PubMed ID: 25592987
[TBL] [Abstract][Full Text] [Related]
18. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P; Orsini F; Lozinsky AC; Gold M; O'Sullivan MD; Quinn P; Lloyd M; Ashley SE; Pitkin S; Axelrad C; Metcalfe JR; Su EL; Tey D; Robinson MN; Allen KJ; Prescott SL; Galvin AD; Tang MLK;
Lancet Child Adolesc Health; 2022 Mar; 6(3):171-184. PubMed ID: 35123664
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.
Greenhawt M; Sindher SB; Wang J; O'Sullivan M; du Toit G; Kim EH; Albright D; Anvari S; Arends N; Arkwright PD; Bégin P; Blumchen K; Bourrier T; Brown-Whitehorn T; Cassell H; Chan ES; Ciaccio CE; Deschildre A; Divaret-Chauveau A; Dorris SL; Dorsey MJ; Eiwegger T; Erlewyn-Lajeunesse M; Fleischer DM; Ford LS; Garcia-Lloret M; Giovannini-Chami L; Hourihane JO; Jay N; Jones SM; Kerns LA; Kloepfer KM; Leonard S; Lezmi G; Lieberman JA; Lomas J; Makhija M; Parrish C; Peake J; Perrett KP; Petroni D; Pfützner W; Pongracic JA; Quinn P; Robison RG; Sanders G; Schneider L; Sharma HP; Trujillo J; Turner PJ; Tuttle K; Upton JE; Varshney P; Vickery BP; Vogelberg C; Wainstein B; Wood RA; Bee KJ; Campbell DE; Green TD; Rouissi R; Peillon A; Bahnson HT; Bois T; Sampson HA; Burks AW
N Engl J Med; 2023 May; 388(19):1755-1766. PubMed ID: 37163622
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy.
Narisety SD; Frischmeyer-Guerrerio PA; Keet CA; Gorelik M; Schroeder J; Hamilton RG; Wood RA
J Allergy Clin Immunol; 2015 May; 135(5):1275-82.e1-6. PubMed ID: 25528358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
